asthma
common
chronic
respiratori
diseas
affect
adult
children
western
world
despit
advanc
asthma
manag
acut
exacerb
continu
occur
impos
consider
morbid
patient
constitut
major
burden
health
care
resourc
respiratori
tract
virus
emerg
frequent
trigger
exacerb
children
adult
howev
mechan
underli
remain
poorli
understood
recent
becom
increasingli
clear
interact
might
exist
virus
trigger
increas
likelihood
exacerb
articl
begin
overview
health
econom
social
burden
exacerb
asthma
carri
follow
review
pathogenesi
asthma
exacerb
highlight
variou
trigger
respons
multipl
interact
exist
final
section
first
address
prevent
measur
current
avail
asthma
exacerb
subsequ
examin
new
treatment
develop
might
lessen
burden
exacerb
futur
j
allergi
clin
immunol
moder
group
sever
group
suggest
frequent
exacerb
relat
diseas
sever
factor
associ
frequent
exacerb
includ
femal
sex
obes
psychopatholog
chronic
sinus
gastroesophag
reflux
respiratori
tract
infect
obstruct
sleep
apnea
therefor
asthmat
patient
experi
frequent
exacerb
unclear
whether
independ
tradit
measur
asthma
control
survey
reallif
asthmat
patient
indic
incid
exacerb
much
higher
seen
patient
recruit
clinic
trial
survey
patient
unit
state
uncontrol
asthma
unschedul
physician
offic
visit
emerg
depart
visit
hospit
last
year
even
patient
control
asthma
unschedul
physician
offic
visit
emerg
depart
visit
hospit
last
year
sever
asthma
research
program
cohort
patient
sever
asthma
ever
attend
emerg
depart
even
mild
moder
group
rate
attend
respect
survey
adult
children
asthma
european
countri
report
children
adult
requir
unschedul
urgent
care
visit
past
month
eighteen
percent
children
adult
requir
emerg
depart
visit
asthma
past
year
patient
requir
overnight
hospit
studi
suggest
asthma
exacerb
common
frequent
result
unschedul
medic
care
although
death
asthma
rel
rare
frequent
associ
poor
asthma
care
therefor
lead
caus
prevent
death
often
young
peopl
death
caus
asthma
adult
children
age
year
unit
state
estim
death
unit
kingdom
number
factor
associ
fatal
nearfat
exacerb
includ
lower
socioeconom
statu
psychiatr
comorbid
femal
sex
older
age
obes
smoke
noncompli
medic
previou
nearfat
attack
therefor
factor
use
identifi
patient
high
risk
asthma
mortal
target
appropri
prevent
measur
social
econom
burden
asthma
exacerb
relat
direct
cost
health
care
use
indirect
cost
associ
lost
product
unit
state
million
million
adult
million
children
asthmarel
emerg
depart
visit
adult
children
asthmarel
hospit
hospit
constitut
one
third
total
billion
us
annual
asthmarel
health
care
expenditur
european
lung
foundat
estim
cost
asthma
european
union
billion
billion
relat
lost
product
realworld
evalu
asthma
control
treatment
survey
adult
children
miss
least
day
work
school
respect
therefor
social
econom
burden
asthma
exacerb
remain
consider
sinc
earli
viral
respiratori
tract
infect
report
trigger
exacerb
asthma
adult
children
develop
highli
sensit
specif
molecular
diagnost
detect
techniqu
use
pcr
technolog
led
greatli
improv
detect
respiratori
tract
virus
allow
clear
demonstr
import
link
viral
infect
asthma
exacerb
pcr
use
supplement
instead
convent
techniqu
virus
found
approxim
wheez
episod
schoolag
children
approxim
one
half
three
quarter
acut
wheez
episod
adult
except
respiratori
syncyti
viru
rsv
infant
hospit
bronchiol
rhinovirus
far
frequent
detect
viru
type
rhinovirus
member
picornavirida
famili
serotyp
predict
pattern
infect
base
serotyp
common
caus
common
cold
children
adult
distribut
worldwid
method
viru
type
classifi
rhinovirus
rva
rvb
group
base
genet
sequenc
similar
suscept
antivir
agent
recent
newli
identifi
group
term
rvc
identifi
base
pure
sequenc
data
interestingli
number
studi
suggest
member
rvc
group
might
intrins
virul
greater
propens
caus
asthma
exacerb
rhinovirus
howev
work
need
better
defin
whether
uniqu
clinic
pictur
associ
rvc
infect
influenza
common
infect
winter
month
frequent
reach
local
nation
epidem
proport
influenza
pandem
number
studi
highlight
asthma
import
comorbid
condit
infect
viru
marker
ill
sever
hospit
admiss
intens
care
unit
mortal
patient
influenza
shown
associ
diagnosi
asthma
rsv
main
pathogen
caus
sever
bronchiol
infant
infect
occur
decemb
februari
year
differenti
among
acut
wheez
bronchiol
postbronchiol
wheez
acut
exacerb
asthma
frequent
difficult
infant
young
children
subsequ
interpret
pediatr
studi
complex
preval
rsv
vari
wide
studi
studi
australian
birth
cohort
studi
rsv
account
second
behind
rhinoviru
case
wheezi
respiratori
tract
infect
first
year
life
wherea
detect
frequenc
seen
similar
british
studi
rsv
older
children
adult
much
less
frequent
howev
seen
older
adult
frequent
underrecogn
trigger
acut
asthma
studi
falsey
et
al
demonstr
hospit
asthma
older
year
associ
rsv
infect
addit
rhinovirus
influenza
rsv
respiratori
tract
virus
coronavirus
human
metapneumovirus
parainfluenza
virus
adenovirus
bocavirus
detect
subject
asthma
exacerb
howev
recent
epidemiolog
studi
perform
discoveri
sever
new
respiratori
tract
virus
bocaviru
viru
type
significantli
associ
asthma
exacerb
children
age
year
rhinovirus
exacerb
asthma
season
import
alway
take
account
season
studi
asthma
exacerb
perform
exampl
studi
infant
carri
septemb
found
case
influenza
wherea
proport
seen
anoth
studi
flu
season
rsv
metapneumovirus
influenza
virus
except
influenza
viru
usual
limit
winter
earli
spring
rhinoviru
infect
occur
throughout
year
common
spring
autumn
children
season
peak
asthma
exacerb
occur
frequent
autumn
correspond
week
start
school
term
phenomenon
term
septemb
epidem
fig
among
older
adolesc
young
adult
similar
albeit
blunt
pictur
seen
peak
occur
week
schoolag
children
older
adult
peak
seen
decemb
januari
septemb
epidem
investig
casecontrol
studi
canadian
group
limit
recruit
children
asthma
exacerb
septemb
virus
detect
case
picornavirus
detect
case
control
subject
view
fact
environment
exposur
includ
allergen
pollut
also
vari
season
seem
probabl
combin
factor
result
season
peak
seen
exacerb
grow
bodi
evid
support
view
viral
infect
allergi
interact
increas
risk
exacerb
green
et
al
report
adult
studi
allergen
sensit
exposur
sensit
allergen
respiratori
tract
viral
infect
act
synergist
manner
significantli
increas
risk
hospit
acut
asthma
four
year
later
murray
et
al
observ
even
greater
synergist
interact
children
factor
alon
parent
smoke
pet
ownership
hous
characterist
increas
risk
hospit
admiss
asthmat
children
murray
sinc
shown
level
ige
antibodi
inhal
antibodi
children
associ
increas
risk
asthma
hospit
quantif
specif
ige
inhal
allergen
predict
exacerb
use
arbitrari
cutoff
serum
ige
concentr
defin
atopi
furthermor
highli
signific
interact
observ
ige
concentr
respiratori
tract
viral
infect
increas
risk
exacerb
follow
concept
atop
statu
spectrum
sever
rather
simpli
ye
diagnosi
simpson
et
al
observ
children
classifi
atop
use
convent
definit
cluster
distinct
class
one
class
term
multipl
earli
sensit
compris
approxim
quarter
atop
children
significantli
associ
risk
hospit
asthma
fig
begin
better
defin
asthma
allergi
phenotyp
appreci
heterogen
disord
better
understand
degre
interact
exist
year
ago
berkovitch
et
al
found
evid
infect
mycoplasma
pneumonia
children
asthma
exacerb
sinc
numer
studi
investig
possibl
associ
bacteria
particular
atyp
organ
pneumonia
chlamydophila
pneumonia
asthma
exacerb
howev
mani
method
detect
organ
standard
insensit
nonspecif
result
across
studi
inconsist
johnston
martin
review
studi
found
demonstr
associ
infect
either
pneumonia
c
pneumonia
exacerb
includ
studi
allegra
et
al
report
evid
atyp
bacteri
infect
c
pneumonia
subject
well
prospect
studi
lieberman
et
al
demonstr
pneumonia
infect
hospit
asthmat
patient
compar
match
control
group
recent
cosentini
et
al
report
acut
infect
c
pneumonia
pneumonia
patient
present
hospit
asthma
exacerb
telicast
studi
serolog
posit
freymuth
et
al
report
modest
infect
rate
c
pneumonia
pneumonia
respect
studi
use
pcr
collect
nasal
aspir
children
hospit
acut
asthma
anoth
studi
children
acut
asthma
show
similar
rate
c
pneumonia
pneumonia
signific
differ
asthmat
patient
control
subject
report
sever
studi
rate
infect
less
highlight
inconsist
natur
associ
atyp
bacteria
asthma
exacerb
wark
et
al
found
one
third
adult
present
acut
sever
asthma
show
increas
c
pneumoniaespecif
antibodi
consist
acut
infect
reinfect
reactiv
latent
infect
c
pneumonia
subject
exhibit
intens
inflammatori
respons
acut
exacerb
exacerb
associ
viral
infect
data
suggest
c
pneumonia
might
act
cofactor
increas
sever
virusinduc
exacerb
although
larg
bodi
data
support
interact
virus
allergi
addit
interest
exist
whether
virus
bacteria
interact
provok
exacerb
observ
respiratori
tract
viral
infect
commonli
preced
bacteri
infect
healthi
subject
chronic
lung
condit
well
describ
oliv
et
al
identifi
virusinduc
impair
antibacteri
host
defens
human
alveolar
macrophag
suggest
viral
infect
might
alter
function
facilit
addit
bacteri
infect
experiment
infect
rhinoviru
subject
without
chronic
obstruct
pulmonari
diseas
mallia
et
al
recent
demonstr
bacteri
infect
volunt
chronic
obstruct
pulmonari
diseas
versu
around
smoke
nonsmok
control
subject
bacteri
infect
detect
baselin
inocul
whether
similar
find
seen
asthmat
patient
requir
studi
note
huang
et
al
hilti
et
al
highlight
increas
divers
lower
airway
bacteri
flora
asthmat
patient
moreov
bacteria
detect
often
virus
recent
studi
acut
episod
wheez
children
less
year
age
similar
studi
requir
older
children
adult
determin
whether
bacteria
play
import
role
age
group
effect
air
pollut
gener
believ
less
virus
aeroallergen
howev
convinc
evid
acut
exposur
specif
pollut
contribut
symptom
increas
sever
asthma
exacerb
number
pollut
appear
contribut
exacerb
asthma
pollut
combust
natur
ga
motor
fuel
nitrogen
dioxid
particul
matter
along
ozon
major
culprit
children
particular
spend
time
outdoor
exercis
therefor
breath
greater
amount
pollut
per
kilogram
bodi
weight
adult
howev
even
indoor
environ
mani
sourc
includ
fireplac
heater
ga
stove
children
asthma
exposur
associ
increas
respiratori
symptom
increas
person
level
associ
increas
sever
virusinduc
exacerb
highlight
potenti
synergist
effect
inflammatori
stimuli
addit
control
exposur
studi
asthmat
patient
demonstr
enhanc
allerg
respons
inhal
allergen
although
difficult
dissect
factor
might
play
role
septemb
epidem
possibl
season
chang
domiciliari
air
pollut
period
increas
risk
virusinduc
exacerb
smoke
among
asthmat
patient
unfortun
common
induc
noneosinophil
pattern
inflamm
rel
corticosteroid
resist
adult
hospit
admiss
emerg
depart
visit
occur
frequent
among
cigarett
smoker
asthma
evid
current
smoke
risk
factor
nearfat
fatal
asthma
relationship
secondhand
smoke
asthma
morbid
children
also
well
recogn
implement
public
smoke
ban
scotland
mackay
et
al
demonstr
reduct
per
year
rate
asthmarel
hospit
children
legisl
implement
admiss
asthma
increas
mean
rate
per
year
studi
europ
unit
state
shown
children
live
smoker
unit
state
episod
childhood
asthma
per
year
attribut
parent
smoke
exacerb
occur
approxim
pregnant
women
asthma
yet
mechan
respons
poorli
understood
exacerb
occur
throughout
pregnanc
howev
appear
cluster
around
late
second
trimest
unsurprisingli
sever
asthma
appear
import
risk
factor
viral
infect
like
common
trigger
although
studi
thu
far
identifi
virus
respons
discontinu
medic
belief
might
harm
fetu
might
also
import
factor
current
guidelin
recommend
stepwis
approach
treatment
aim
maintain
control
matern
asthma
throughout
pregnanc
relationship
psycholog
factor
stress
asthma
outcom
describ
centuri
lead
term
asthma
nervosa
sever
life
event
either
isol
conjunct
high
level
chronic
stress
shown
significantli
increas
risk
exacerb
children
asthma
similar
find
identifi
adult
sandberg
et
al
assess
children
asthma
period
demonstr
immedi
risk
exacerb
within
day
sever
neg
life
event
delay
increas
risk
week
sever
event
psycholog
factor
influenc
adher
treatment
clinic
followup
howev
miller
chen
demonstr
diminish
express
glucocorticoid
b
adrenerg
receptor
gene
asthmat
children
experienc
acut
chronic
stress
rel
asthmat
children
without
compar
stressor
exposur
reduct
glucocorticoid
receptor
mrna
reduct
b
receptor
mrna
prevent
exacerb
oppos
treat
exacerb
establish
could
reduc
social
financi
burden
asthma
exacerb
sever
commonli
use
asthma
therapeut
demonstr
reduc
frequenc
asthma
exacerb
novel
biolog
also
shown
potenti
respiratori
tract
viral
infect
remain
predomin
caus
asthma
exacerb
prevent
infect
vaccin
potenti
effect
strategi
prevent
exacerb
effect
vaccin
exist
rhinoviru
infect
common
caus
asthma
exacerb
antigen
divers
multipl
serotyp
therefor
vaccin
program
concentr
mainli
influenza
virus
influenza
infect
associ
asthma
exacerb
mani
studi
influenza
vaccin
asthmat
patient
strongli
recommend
vaccin
pandem
influenza
specif
recommend
asthmat
patient
safe
effect
induc
seroprotect
combin
season
influenza
vaccin
asthma
commonli
identifi
comorbid
associ
increas
diseas
sever
recent
pandem
emphas
import
role
vaccin
howev
note
although
sever
studi
inde
demonstr
reduct
number
exacerb
vaccin
studi
shown
clear
benefit
pharmacolog
strategi
ic
treatment
reduc
risk
asthma
exacerb
inhal
budesonid
therapi
decreas
exacerb
patient
newli
diagnos
mild
persist
asthma
requir
fewer
cours
system
corticosteroid
compar
patient
receiv
placebo
highdos
budesonid
treatment
also
reduc
asthma
exacerb
nearli
adult
asthmat
patient
whose
symptom
poorli
control
despit
moder
ic
treatment
benefit
show
dose
respons
signific
reduct
annual
sever
exacerb
also
observ
adult
patient
milder
asthma
previous
prescrib
ic
treatment
reduc
exacerb
risk
ic
treatment
also
demonstr
children
mode
action
inhal
steroid
prevent
virusinduc
exacerb
poorli
understood
howev
skevaki
et
al
demonstr
corticosteroid
budesonid
effect
suppress
rhinovirusmedi
induct
proinflammatori
remodelingassoci
fibroblast
growth
factor
vascular
endotheli
growth
factor
mediat
bronchial
epitheli
cell
bec
concentrationdepend
manner
exacerb
also
prevent
combin
treatment
icss
laba
combin
budesonid
formoterol
effect
budesonid
alon
annual
exacerb
reduc
highdos
budesonid
dose
combin
formoterol
effect
also
reproduc
icslaba
combin
edward
et
al
demonstr
combin
treatment
synergist
suppress
induct
rhinovirusinduc
chemokin
bec
combin
therapi
budesonid
formoterol
use
prevent
reliev
also
demonstr
reduc
asthma
exacerb
adult
leukotrien
receptor
antagonist
might
also
prevent
asthma
exacerb
patient
mild
asthma
children
age
year
bisgaard
et
al
demonstr
reduct
rate
asthma
exacerb
montelukast
compar
placebo
period
recent
trial
demonstr
benefit
acut
exacerb
addon
therapi
howev
although
earlier
trial
montelukast
treatment
shown
reduc
risk
exacerb
peak
follow
summer
vacat
children
recent
trial
show
signific
benefit
reduc
percentag
day
worsen
asthma
initi
start
school
year
mab
develop
mab
molecular
target
identifi
import
patient
allerg
asthma
shown
earli
potenti
prevent
asthma
exacerb
antiig
ige
key
role
develop
allergi
influenc
allergen
uptak
dendrit
cell
activ
mast
cell
human
antiig
mab
omalizumab
licens
use
patient
asthma
symptom
despit
maxim
therapi
treatment
result
reduct
highaffin
ige
receptor
densiti
reduc
mast
cell
degranul
associ
signific
reduct
asthma
exacerb
adult
allerg
asthmat
patient
omalizumab
effect
reduc
asthma
exacerb
given
addit
ic
treatment
odd
ratio
period
steroid
wean
odd
ratio
associ
reduct
number
durat
exacerb
omalizumab
treatment
also
shown
effect
children
random
trial
multipl
exacerb
despit
ic
treatment
reduct
clinic
signific
exacerb
observ
treat
group
period
adolesc
moderatetosever
allerg
asthma
despit
ic
treatment
also
report
requir
fewer
asthmarel
system
corticosteroid
cours
omalizumab
treatment
h
cytokin
essenti
matur
differenti
eosinophil
mepolizumab
mab
initi
report
reduc
blood
eosinophil
number
patient
mild
asthma
effect
clinic
asthma
paramet
subsequ
trial
patient
sever
asthma
demonstr
addit
reduc
blood
sputum
eosinophil
number
mepolizumab
treatment
associ
reduc
asthma
exacerb
improv
asthmarel
qualiti
life
addit
studi
patient
sever
asthma
demonstr
reduct
exacerb
frequenc
reduct
prednisolon
requir
month
mepolizumab
treatment
although
encourag
studi
demonstr
mepolizumab
treatment
might
effect
patient
sever
steroidrefractori
asthma
sputum
eosinophilia
unlik
help
asthmat
patient
without
evid
eosinophilia
mab
addit
antiig
mab
develop
cytokin
implic
allerg
respons
earli
target
role
ige
product
suppress
h
immun
mucin
secret
adhes
molecul
express
moreov
experiment
infect
rhinoviru
messag
et
al
observ
augment
level
implic
increas
sever
asthma
exacerb
although
initi
trial
solubl
receptor
blocker
disappoint
recent
result
encourag
recent
trial
lebrikizumab
demonstr
signific
reduct
rate
exacerb
howev
hight
h
subgroup
rate
exacerb
lower
lebrikizumab
group
placebo
group
tnfa
proinflammatori
cytokin
involv
upregul
adhes
molecul
mucin
secret
airway
remodel
also
target
initi
investig
patient
sever
asthma
high
tnfa
level
treat
recombin
human
tnfa
receptor
blocker
etanercept
demonstr
improv
fev
qualiti
life
despit
encourag
start
studi
patient
sever
asthma
treat
antitnfa
antibodi
golimumab
show
chang
pulmonari
function
exacerb
rate
studi
discontinu
earli
seriou
side
effect
bronchial
thermoplasti
reduc
airway
smooth
muscl
mass
ablat
central
airway
radiofrequ
energi
bronchoscopi
earli
studi
demonstr
reduct
mild
exacerb
perform
patient
sever
asthma
year
bronchial
thermoplasti
mild
asthma
exacerb
significantli
reduc
month
vs
untreat
group
author
extrapol
fewer
mild
exacerb
per
year
differ
observ
sever
exacerb
signific
reduct
sever
exacerb
demonstr
adult
sever
asthma
random
thermoplasti
sham
procedur
howev
expens
postprocedur
hospit
treatment
group
reduc
emerg
depart
visit
workschool
absenc
also
observ
thermoplasti
group
year
procedur
reduct
sever
exacerb
recent
demonstr
persist
year
despit
posit
result
thermoplasti
unlik
wide
use
time
consum
administ
recent
year
becom
increasingli
clear
immunemodulatori
effect
macrolid
antibiot
exist
distinct
antimicrobi
action
jang
et
al
demonstr
reduc
express
intercellular
adhes
molecul
treatment
erythromycin
rhinovirusinfect
epitheli
cell
gielen
et
al
show
pretreat
bec
azithromycin
significantli
increas
type
iii
interferon
interferonstimul
gene
mrna
protein
express
addit
azithromycin
reduc
rhinoviru
replic
releas
howev
strunk
et
al
demonstr
superior
azithromycin
placebo
studi
children
primari
outcom
time
random
inadequ
asthma
control
case
rsv
treatment
infant
bronchiol
clarithromycin
led
reduc
system
inflamm
acut
fewer
wheez
episod
follow
month
although
small
studi
much
larger
studi
asthmat
adult
random
receiv
either
telithromycin
ketolid
antibiot
placebo
result
greater
reduct
asthma
symptom
score
lung
function
ketolidetr
group
safeti
concern
limit
widespread
use
telithromycin
studi
need
clarifi
posit
macrolid
manag
asthma
exacerb
patient
educ
selfmanag
one
nonpharmacolog
approach
rightli
emphas
recent
year
role
patient
educ
combin
selfmanag
convincingli
demonstr
asthma
morbid
reduc
selfmanag
program
includ
selfmonitor
written
action
plan
regular
medic
review
asthma
educ
adult
risk
admit
hospit
decreas
present
emerg
depart
asthma
decreas
similar
pattern
also
seen
children
effect
written
action
plan
base
symptom
peak
expiratori
flow
pef
use
action
point
pefbas
plan
use
personalbest
pef
rather
percent
predict
pef
former
consist
improv
health
outcom
wherea
latter
appear
addit
instruct
regard
treatment
exacerb
includ
icss
oral
corticosteroid
abil
predict
exacerb
could
signific
effect
asthma
manag
meltzer
et
al
recent
found
signific
correl
measur
asthma
control
questionnair
acq
valid
composit
measur
asthma
control
risk
futur
asthma
exacerb
although
unrealist
expect
adher
full
daili
diari
record
requir
studi
shorter
version
acq
could
potenti
assess
patient
outsid
clinic
set
assess
risk
asthma
exacerb
addit
mab
describ
number
novel
target
current
develop
potenti
prevent
reduc
frequenc
sever
asthma
exacerb
one
target
inhal
ifnb
interest
target
first
aros
work
corn
et
al
demonstr
sever
prolong
virusinduc
asthma
symptom
asthmat
compar
nonasthmat
subject
wark
et
al
subsequ
provid
evid
bec
asthmat
patient
produc
lower
level
type
ifnb
also
show
higher
level
rhinoviru
replic
bec
asthmat
patient
respond
exogen
treatment
ifnb
exhibit
reduc
rhinoviru
releas
demonstr
defici
asthmat
cell
associ
product
antivir
ifnb
rather
action
ifnb
result
suggest
deliveri
ifnb
lower
airway
cold
develop
might
result
restor
antivir
defens
lung
asthmat
patient
limit
result
inflamm
thu
either
prevent
reduc
sever
exacerb
importantli
boost
host
defens
rather
target
specif
respiratori
tract
virus
ifnb
anticip
broad
antivir
activ
result
phase
proofofconcept
trial
ifnb
therapi
await
interest
similar
defici
antivir
type
iii
ifnl
observ
asthmat
patient
interferon
also
recent
report
profoundli
suppress
allerg
airway
inflamm
thu
famili
interferon
also
potenti
treatment
great
interest
becderiv
cytokin
thymic
stromal
lymphopoietin
look
like
increasingli
interest
target
asthmat
patient
next
year
like
see
surg
studi
import
mediat
current
mab
direct
thymic
stromal
lymphopoietin
amg
phase
develop
antibodi
block
activ
test
success
anim
model
asthma
influenzainduc
airway
hyperreact
interest
target
current
investig
tolllik
receptor
tlr
agonist
receptor
viral
singlestrand
rna
signal
adaptor
molecul
activ
transcript
factor
induc
product
rang
antivir
inflammatori
cytokin
interferon
tnfa
kaufman
et
al
recent
test
effect
synthet
agonist
imiquimod
guinea
pig
vivo
demonstr
inhibit
bronchoconstrict
within
minut
administr
novel
mechan
limit
bronchoconstrict
respiratori
tract
infect
addit
antivir
properti
establish
year
ago
make
compound
attract
candid
asthma
treatment
addit
excit
target
mani
approach
current
develop
kinas
inhibitor
phosphodiesteras
inhibitor
howev
full
review
beyond
scope
articl
one
primari
goal
manag
asthma
minim
risk
futur
exacerb
respiratori
virus
well
accept
main
trigger
exacerb
despit
emerg
newli
discov
virus
rhinovirus
remain
common
pathogen
detect
understand
mechan
provok
virusinduc
airway
inflamm
asthmat
patient
like
offer
signific
opportun
improv
diseas
manag
howev
realiti
present
current
drug
treatment
virusinduc
exacerb
poorli
effect
altern
therapi
modul
viral
pathogenesi
desper
need
end
experiment
human
murin
model
rhinovirusinduc
asthma
exacerb
develop
offer
great
potenti
increas
mechanist
understand
well
provid
us
model
test
potenti
new
therapi
studi
clearli
requir
better
understand
complic
relationship
exist
among
virus
bacteria
allerg
inflamm
despit
develop
newer
asthma
medic
recent
survey
asthmat
patient
highlight
year
percentag
seek
acut
care
asthma
preced
month
chang
significantli
sober
truth
indic
much
still
need
